Title:The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials
Volume: 26
Issue: 46
Author(s): Stavroula A. Paschou, Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos Oikonomou, Alexios S. Antonopoulos, Konstantinos Batzias, Vasiliki Tsigkou, Konstantinos Mourouzis, Andromachi Vryonidou, Nikolaos Tentolouris, Manolis Vavouranakis and Dimitrios Tousoulis
Affiliation:
- First Department of Cardiology, “Hippokration” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens,Greece
Keywords:
Type 2 diabetes mellitus, DPP-4 inhibitors, endothelial function, arterial stiffness, cardiovascular health, molecular cardiology.
Abstract: We systematically reviewed the literature regarding the impact of dipeptidyl peptidase-4 inhibitors
(DPP-4i) on vascular function, including endothelial function and arterial stiffness, as predictors of atherosclerosis
progression and cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). We searched
PubMed in order to identify clinical trials that investigated the effect of DPP-4i on vascular function in patients
with T2DM when compared with placebo. Although 168 articles were initially found, only 6 studies (total 324
patients) investigated the effect of DPP-4i in comparison with placebo, specifically linagliptin and sitagliptin,
and satisfied the inclusion criteria. There are scarce data to indicate that linagliptin may enhance endothelial
function and exert a slight beneficial effect on arterial wall properties. Sitagliptin seems to have a neutral effect
on these variables. Further trials are needed to elucidate the topic. The standards of reporting were in accordance
with the PRISMA guidelines.
